2013-02-27 15:32:27 -
Mentor, Ohio (February 27, 2013) - STERIS Corporation (NYSE: STE) today
announced that Michael J. Tokich, Senior Vice President and Chief Financial
Officer of STERIS Corporation, will present at the Raymond James Institutional
Investor Conference at 12:45 p.m., eastern time on Wednesday, March 6, 2013.
The presentation can be accessed live via webcast on STERIS Corporation's
investor relations website at www.steris-ir.com, and will be archived on the
site.
About STERIS
The mission of STERIS Corporation is to provide a healthier today and safer
tomorrow through knowledgeable people and innovative infection prevention,
decontamination and health science technologies, products and services. The
Company has approximately 6,000 dedicated employees around the world working
together to supply a broad array of solutions by offering a combination of
equipment, consumables and services to healthcare, pharmaceutical, industrial
and government Customers.
The Company is listed on the New York Stock Exchange
under the symbol STE. For more information, visit www.steris.com.
This press release and the referenced presentation may contain statements
concerning certain trends, expectations, forecasts, estimates, or other forward-
looking information affecting or relating to the Company or its industry,
products or activities that are intended to qualify for the protections afforded
"forward-looking statements" under the Private Securities Litigation Reform Act
of 1995 and other laws and regulations. Forward-looking statements speak only as
to the date made, and may be identified by the use of forward-looking terms such
as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates,"
"projects," "targets," "forecasts," "outlook,"
"impact," "potential,"
"confidence," "improve," "optimistic," "deliver,"
"comfortable," "trend", and
"seeks," or the negative of such terms or other variations on such terms or
comparable terminology. Many important factors could cause actual results to
differ materially from those in the forward-looking statements including,
without limitation, disruption of production or supplies, changes in market
conditions, political events, pending or future claims or litigation,
competitive factors, technology advances, actions of regulatory agencies, and
changes in laws, government regulations, labeling or product approvals or the
application or interpretation thereof. Other risk factors are described herein
and in the Company's Form 10-K and other securities filings. Many of these
important factors are outside STERIS's control. No assurances can be provided as
to any result or the timing of any outcome regarding matters described in this
press release or the referenced presentation or otherwise with respect to any
regulatory action, administrative proceedings, government investigations,
litigation, warning letters, consent decree, rebate program, transition, cost
reductions, business strategies, earnings or revenue trends or future financial
results (including without limitation the settlement of the SYSTEM 1 class
action litigation and the regulatory matters related to SYSTEM 1E or its
accessories). References to products, the consent decree, the transition or
rebate program, or the class action settlement, are summaries only and should
not be considered the specific terms of the decree, settlement, program or
product clearance or literature. Unless legally required, the Company does not
undertake to update or revise any forward-looking statements even if events make
clear that any projected results, express or implied, will not be realized.
Other potential risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements include, without
limitation, (a) the potential for increased pressure on pricing or costs that
leads to erosion of profit margins, (b) the possibility that market demand will
not develop for new technologies, products or applications or the Company's
business initiatives will take longer, cost more or produce lower benefits than
anticipated, (c) the possibility that application of or compliance with laws,
court rulings, certifications, regulations, regulatory actions, including
without limitation those relating to FDA warning notices or letters, government
investigations, the April 20, 2010 consent decree, the SYSTEM 1E device, the
outcome of any pending FDA requests, inspections or submissions, or other
requirements or standards may delay, limit or prevent new product introductions,
affect the production and marketing of existing products or services or
otherwise affect Company performance, results, prospects or value, (d) the
potential of international unrest, economic downturn or effects of currencies,
tax assessments, adjustments, or anticipated rates, raw material costs or
availability, benefit or retirement plan costs, or other regulatory compliance
costs, (e) the possibility of reduced demand, or reductions in the rate of
growth in demand, for the Company's products and services, (f) the possibility
that anticipated growth, cost savings, new product acceptance, performance or
approvals, including without limitation SYSTEM 1E and accessories thereto, or
other results may not be achieved, or that transition, labor, competition,
timing, execution, regulatory, governmental, or other issues or risks associated
with our business, industry or initiatives including, without limitation, the
consent decree, and the transition from the SYSTEM 1 processing system and
adjustments to related reserves, or those matters described in our Form 10-K for
the year ended March 31, 2012 and other securities filings, may adversely impact
Company performance, results, prospects or value, (g) the possibility that
anticipated financial results or benefits of recent acquisitions will not be
realized or will be other than anticipated, (h) the effect of the contraction in
credit availability, as well as the ability of our Customers and suppliers to
adequately access the credit markets when needed, and (i) those risks described
in our securities filings including our Annual Report on Form 10-K for the year
ended March 31, 2012, and other securities filings.
Contact: Julie Winter, Director, Investor Relations at 440-392-7245.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Steris Corporation via Thomson Reuters ONE
[HUG#1681630]
